Navigation Links
OrbusNeich Announces Favorable Ruling From the European Patent Office
Date:2/12/2013

FORT LAUDERDALE, Fla., Feb. 12, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich") announced that it received a favorable ruling from the European Patent Office ("EPO") yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures.  It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021.  

In July 2011, Boston Scientific Corporation (NYSE: BSX) and Terumo Kabushiki Kaisha filed oppositions asking the EPO to revoke the '482 patent, asserting that the patent was invalid.  In response, OrbusNeich amended the claim of the '482 patent to more clearly identify the scope of its novel, helical stents.  During oral proceedings held yesterday in The Hague, the EPO upheld the claim of the '482 patent as amended.  

OrbusNeich believes that the claim of the '482 patent is infringed by current lines of Boston Scientific's stent systems.  OrbusNeich is committed to maintaining and enforcing patent protection for all of its intellectual property and innovations.  The Company is evaluating all options related to its stent patent portfolio.   

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Global Media Contacts:
Dan Katcher / Jamie Moser
Joele Frank , Wilkinson Brimmer Katcher
(212) 355-4449


'/>"/>
SOURCE OrbusNeich Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
3. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
5. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
6. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
7. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. NASP Announces Partnership with Gerry Crocker to Advance Specialty Pharmacy Industry
11. American Outcomes Management, L.P. announces the appointment of Patrick S. Smith as President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):